Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alimera’s Alaway Follows Novartis’ Zaditor To Spring 2007 OTC Launch

This article was originally published in The Tan Sheet

Executive Summary

Alimera Sciences plans to launch its Alaway over-the-counter ophthalmic solution at the same time as its bioequivalent competitor, Novartis' Zaditor.

You may also be interested in...



B&L buys Alaway

Alimera Sciences and Bausch & Lomb announce Dec. 20 B&L has purchased Alimera's OTC allergy franchise, including recently-approved Alaway, for an undisclosed amount. "The acquisition of Alaway not only enhances our current OTC product portfolio by giving us a stronger and longer-lasting product to address the needs of consumers who suffer itchy eyes, but it also gives us an excellent technology platform for the development of product line extensions in the ocular allergy category," B&L Corporate VP and Global Pharmaceutical Category Leader Gary M. Phillips, M.D., says. Alimera Sciences announced FDA's approval of Alaway Dec. 5 (1"The Tan Sheet" Dec. 11, 2006, p. 7)...

B&L buys Alaway

Alimera Sciences and Bausch & Lomb announce Dec. 20 B&L has purchased Alimera's OTC allergy franchise, including recently-approved Alaway, for an undisclosed amount. "The acquisition of Alaway not only enhances our current OTC product portfolio by giving us a stronger and longer-lasting product to address the needs of consumers who suffer itchy eyes, but it also gives us an excellent technology platform for the development of product line extensions in the ocular allergy category," B&L Corporate VP and Global Pharmaceutical Category Leader Gary M. Phillips, M.D., says. Alimera Sciences announced FDA's approval of Alaway Dec. 5 (1"The Tan Sheet" Dec. 11, 2006, p. 7)...

B&L buys Alaway

Alimera Sciences and Bausch & Lomb announce Dec. 20 B&L has purchased Alimera's OTC allergy franchise, including recently-approved Alaway, for an undisclosed amount. "The acquisition of Alaway not only enhances our current OTC product portfolio by giving us a stronger and longer-lasting product to address the needs of consumers who suffer itchy eyes, but it also gives us an excellent technology platform for the development of product line extensions in the ocular allergy category," B&L Corporate VP and Global Pharmaceutical Category Leader Gary M. Phillips, M.D., says. Alimera Sciences announced FDA's approval of Alaway Dec. 5 (1"The Tan Sheet" Dec. 11, 2006, p. 7)...

Topics

UsernamePublicRestriction

Register

LL1126093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel